LifeSci Advisors, LLC
23.6.2017 17:54 | Nasdaq OMX
LifeSci Advisors' Board Placement Initiative Announces Ninth Board Placement
NEW YORK, June 23, 2017 (GLOBE NEWSWIRE) -- LifeSci Advisors , a leading life sciences-focused investor relations consultancy, announced today the ninth placement of a female executive to a life sciences company board as part of their Board Placement Initiative (BPI), a program launched a year ago with the goal to connect female executives in the life sciences industry with companies looking for board candidates. LifeSci is pleased to share news of the appointment of Jean M. Franchi to the Board of Directors of Biophytis, a biotech company listed on Euronext Paris (ALBPS) focused on drugs that target diseases of aging, with drug candidates in clinical development for dry AMD and Sarcopenia.
"I'm honored to join the Biophytis board, and look forward to helping the company achieve a more global presence as it advances its portfolio of innovative therapies addressing unmet needs associated with aging," said Ms. Franchi . "I want to extend my kind thanks to LifeSci for the introduction through its important initiative, BPI."
Ms. Franchi brings more than 30 years of financial experience in biotechnology, including her role as Chief Financial Officer of Dimension Therapeutics and, previously, Good Start Genetics. At Dimension, she played a significant role in successfully introducing the company onto the NASDAQ stock exchange in 2015. Previously, Ms. Franchi spent 16 years at Genzyme Corporation, where she held roles of increasing responsibility and was instrumental in preparing the company for its transition from early market introductions to becoming the industry leader in rare disease drug development and commercialization. Earlier in her career, Ms. Franchi worked in accounting, finance, and sales operations for two diagnostic companies: bioMérieux, Inc., and API, a former division of American Home Products (now Pfizer).
"Jean's decades of experience in finance and success with the biotech IPO process will make her an asset to the Biophytis board," said Michael Rice, Founding Partner, LifeSci Advisors . "We are thrilled that LifeSci Advisors' Board Placement Initiative has been able to play a role in facilitating this appointment."
LifeSci Advisors' Board Placement Initiative is accepting resumes from interested candidates and referrals on an ongoing basis. Resumes or open board seat positions can be sent to email@example.com . You can find out more information about BPI and LifeSci Advisors' commitment to board diversity by visiting www.lifesciadvisors.com/board-diversity-initiatives .
About LifeSci Advisors, LLC:
LifeSci Advisors, LLC (www.lifesciadvisors.com ) is a unique investor relations consultancy founded to provide companies in the life sciences a comprehensive solution to investor communications and outreach. With a local presence in New York, Boston, Chicago, Philadelphia, London, Geneva and Tel Aviv, the firm provides the highest quality service for its clients through its deep sector specialization. Our roster of PhDs enables us to better understand our clients' R&D, regulatory, and commercial strategy, and our team of capital markets, investor relations, and public relations specialists help our clients effectively communicate to the marketplace. This combination of life sciences, capital markets, and investor relations competencies allows us to provide a valuable and highly differentiated service offering to our clients.
About LifeSci Partners:
LifeSci Partners (www.lifescipartners.com ) is the leading provider of comprehensive consulting services in the areas of investor relations, corporate communications, public relations and capital markets advisory. Combining deep domain expertise in the life sciences and decades of experience in capital markets and public relations, we deliver unparalleled services to life sciences companies globally. LifeSci Partners has a physical presence in New York, Boston, Chicago, Philadelphia, London, Geneva and Tel Aviv.
For further information, please contact:
LifeSci Advisors, LLC
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Ved at skrive dig op her, vil du modtage pressemeddelelser på mail når de udsendes. Indtast din mail og følg instruktionerne. Det er ligeså let at melde sig fra igen.
Flere pressemeddelelser fra Nasdaq OMX
Promethean, Inc.18.8.2017 18:40 | pressemeddelelse
Promethean Opens New Global Headquarters in Seattle
Hminers18.8.2017 11:01 | pressemeddelelse
Hminers Disrupts the Cryptocurrency Market with Powerful, Multi-Algorithm Mining Rigs
Nasdaq17.8.2017 18:51 | pressemeddelelse
Nasdaq Welcomes I-AM Capital Acquisition Company (Nasdaq: IAMXU) to The Nasdaq Stock Market
Tetraphase Pharmaceuticals17.8.2017 14:31 | pressemeddelelse
Tetraphase Pharmaceuticals Announces Submission and Validation of IV Eravacycline Marketing Authorization Application by European Medicines Agency
RedHill Biopharma Ltd.17.8.2017 13:01 | pressemeddelelse
RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules
Safway Group16.8.2017 19:41 | pressemeddelelse
Brand Industrial Services Announces Agreement to Acquire Venko Groep BV
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum